The SGLT-2 inhibitor market, which surpassed 150 billion won in annual prescriptions last year, also grew 15% in the first quarter, surpassing 40 billion won in quarterly prescriptions. single and combination drugs have grown evenly.

According to UBIST, a pharmaceutical market research firm, on the 28th, the total amount of outpatient prescriptions for SGLT-2 inhibitors in the first quarter was 40.2 billion won, up 15.0% from 34.8 billion won a year earlier. The quarterly prescription for SGLT-2 inhibitors, which was in the early 20 billion won in 2019, has nearly doubled in two years.

The SGLT-2 inhibitor has been released as a type 2 diabetes treatment, expanding the disease group to the h